Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771724 | 0.76 | SIGMAR1 (0.39) | SIGMAR1FDPSALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL3843060 | 0.73 | SIGMAR1 (0.33) | SIGMAR1FDPSALDH1A1 | |
| SCHEMBL1474688 | 0.73 | DUT (0.35) | SIGMAR1FDPSALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL29823262 | 0.73 | DUT (0.35) | SIGMAR1FDPSALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3940682 | 0.72 | BACE1 (0.44) | FDPSALDH1A1 | |
| SCHEMBL2488880 | 0.72 | ALDH1A1 (0.42) | SIGMAR1ALDH1A1KDM4EHPGDRCE1 | |
| SCHEMBL12585350 | 0.71 | SIGMAR1 (0.36) | SIGMAR1FDPSALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL8069572 | 0.71 | DUT (0.39) | SIGMAR1FDPSCYP1A2CYP2C19 | |
| SCHEMBL15716638 | 0.69 | SIGMAR1 (0.39) | SIGMAR1FDPSALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL11600164 | 0.69 | ALDH1A1 (0.40) | SIGMAR1FDPSALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550510-B2 | Solid phase synthesis of arylretinamides | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-27 | — | — | US | disclosed |
| US-6696606-B2 | REACTING HEXACHLOROACETONE WITH TRIPHENYLPHOSPHINE; CHLORINATION OF RETINOIC ACID; THEN AROMATIC AMINE; ANTICANCER AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2004-02-24 | — | — | US | disclosed |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-05 | — | — | US | disclosed |
| WO-2003003987-A2 | SOLID PHASE SYNTHESIS OF ARYLRETINAMIDES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | SIGMAR1 3864/4885FDPS 1566/4885ALDH1A1 1637/4885 |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | SIGMAR1 3864/4885FDPS 1566/4885ALDH1A1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.